<DOC>
	<DOCNO>NCT02769481</DOCNO>
	<brief_summary>The purpose study investigate effect bexagliflozin compare glimepiride add-on therapy metformin lower hemoglobin A1c ( HbA1c ) level subject type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Safety Efficacy Bexagliflozin Compared Glimepiride Add-on Therapy Metformin Type 2 Diabetes Subjects</brief_title>
	<detailed_description>Approximately 420 subject inadequately control T2DM metformin recruit North America Europe . Subjects randomly assign receive bexagliflozin tablet , 20 mg , glimepiride capsule , 2 , 4 6 mg , ratio 1:1 daily 96 week . Subjects continue take metformin duration study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosis T2DM Currently take metformin take metformin one additional oral medication diabetes Body Mass Index ( BMI ) â‰¤ 45 kg/m2 Stable dose blood pressure cholesterol medication ( applicable ) least 30 day Hypersensitivity contraindication safe use sulfonylurea glimepiride Diagnosis type 1 diabetes mellitus maturityonset/diabetes young Current use inject therapy treatment diabetes ( insulin GLP1 receptor agonist therapy ) thiazolidinedione class drug History genitourinary tract infection Evidence abnormal liver function Myocardial infarction , stroke hospitalization heart failure within 3 month screen Prior kidney transplant evidence kidney problem Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>